Two-Stage PEG Precipitation for Non-Enveloped Virus Purification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for producing non-enveloped virus particles, such as adeno-associated virus (AAV), face challenges in achieving high purity and efficiency due to complex and inadequate purification processes, often resulting in contamination and impurities.
Innovation Solution
A method involving a two-stage polyethylene glycol (PEG) concentration process is used to purify non-enveloped virus particles, where a first PEG concentration precipitates impurities, and a higher second PEG concentration separates the virus particles from soluble impurities, enhancing purity and simplifying the process.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If conventional purification methods (filtration, ultracentrifugation, chromatography, ultrafiltration) are used to purify rAAV particles, then virus particles can be obtained, but the purification process is complex and time-consuming
Solution Approach 1:
The invention changes the concentration parameter of PEG to create different precipitation conditions. By using a first PEG concentration (1-10% w/v) to precipitate impurities and then a second PEG concentration (10-30% w/v) to precipitate virus particles, the method simplifies the purification process while achieving high purity rAAV particles
Solution Approach 2:
The invention utilizes phase transition through PEG-induced precipitation. Impurities and virus particles are separated by controlling their phase transition from dissolved state to precipitated state at different PEG concentrations, enabling simple yet effective purification
2Manufacturing precision
If conventional purification methods are used, then virus particles can be purified, but the process requires many steps including two-phase separation, precipitation, treatment with chloroform, and dialysis
Solution Approach 1:
The invention extracts and removes impurities from the virus particle solution by selective precipitation. First, impurities are extracted by precipitation at low PEG concentration, then virus particles are extracted by precipitation at high PEG concentration, achieving purification in just two steps without complex procedures
Solution Approach 2:
The purification process is segmented into two distinct stages based on PEG concentration: first stage precipitates impurities at 1-10% PEG, second stage precipitates virus particles at 10-30% PEG. This segmentation allows simple sequential operation without complex multi-step procedures
3Productivity
If a single high concentration of PEG is used for precipitation, then virus particles can be precipitated, but impurities remain in the precipitate
Solution Approach 1:
The invention performs preliminary precipitation of impurities at low PEG concentration (1-10% w/v) before the main precipitation of virus particles at high PEG concentration (10-30% w/v). This preliminary action removes impurities that would otherwise co-precipitate with virus particles, ensuring high purity while maintaining yield
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method effectively produces non-enveloped virus particles with high purity, reducing laborious operations and improving the yield, making them suitable for gene therapy applications.
Implementation Method 1
treating a sample containing a non-enveloped virus particle with a first concentration of polyethylene glycol (PEG)... a step of removing a precipitate produced in step (a)
Implementation Method 2
treating a supernatant with a second concentration of PEG... a step of obtaining a non-enveloped virus particle from a precipitate produced in step (b)
Data Source
AI summary
Provided are a production method for non-enveloped virus particles which is characterized in that a sample including non-envelopes virus particles is treated with PEG in at least two concentrations; a kit used in said production method; non-enveloped virus particles produced using said production method; and a pharmaceutical composition having the non-envelopes virus particles as an active ingredient.